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DRUG RESISTANCE IN TUBERCULOSIS AND ISSUES RELATED TO 
MULTIDRUG RESISTANCE IN PLANNING FOR TB CONTROL 
P.VENKATARAMAN & C.N.PARAMASIVAN* 
There is no clear evidence of an increase in the prevalence of initial drug resistance in India over the 
years. However, relatively high prevalence of acquired resistance has been reported. The level of initial 
drug resistance is said to be an epidemiological marker to assess the success of the National TB 
Programme. This also influences the design of the regimens to be employed as well as policy decisions. 
I. INTRODUCTION 
Although the phenomenon of drug resistance in 
M. tuberculosis was observed even in the early days 
of chemotherapy nearly 50 years ago, the current 
threat is due to the emergence of strains resistant to 
the two most potent anti-TB drugs viz., isoniazid (H) 
and rifampicin (R) (MDR-TB). Despite TB being 100% 
curable, patients develop drug resistance tuberculosis 
due to various reasons. The level of initial drug 
resistance is said to be an epidemiological marker to 
assess the success of the National TB Programme. 
This also influences the design of the regimens to be 
employed as well as policy decisions. The response of 
patients with MDR-TB to treatment is poor and the 
mortality rate is usually high. Since these patients 
need to be treated with expensive and toxic second- 
line drugs, and may require hospitalization to manage 
their toxic reactions and other complications, they 
require a sizeable proportion of health care resources. 
Further, an alarming increase in infection due 
to the human immunodeficiency virus (HIV) has 
accelerated this situation and it is believed that, as of 
now, about 3.5 million people in India are infected with 
HIV(1). The HIV infection is the strongest risk factor 
for TB infection to develop into active TB and it is also 
known that the rate of progression from TB infection 
to active disease is 10-30 times higher among persons 
with HIV and TB than among those with TB infection 
alone. Thus, there is a grave concern in India regarding 
the increase in HIV-associated TB and the emergence 
of MDR-TB in both magnitude and severity of TB 
epidemic. 
II. DEFINITION OF DRUG RESISTANCE 
Professor Mitchison defined drug resistance in 
mycobacteria as a decrease in sensitivity to a sufficient 
degree to be reasonably certain that the strain 
concerned is different from a sample of wild strains of 
human type that have never in contact with the 
drugs(2). 
A. Types of drug resistance 
Drug resistance in TB may be broadly classified 
as primary or acquired. When drug resistance is 
demonstrated in a patient who has never received anti- 
TB treatment previously, it is termed primary 
resistance. Acquired resistance is that which occurs 
as a result of specific previous treatment. Some 
workers prefer a working definition, viz., initial 
resistance to indicate primary resistance and 
undisclosed acquired resistance. This is common since 
sometimes patients are unaware that they, have 
received anti TB treatment at all or they may 
sometimes conceal their history of previous treatment. 
Transient resistance occurs just before sputum 
conversion in a patient who is responding to therapy. 
This normally occurs in the form of a few resistant 
colonies which usually do not multiply and does not 
warrant a change of treatment. The level of primary 
resistance in the community is considered to reflect 
the efficacy of control measures in the past, while the 
level of acquired resistance is a measure of on-going 
TB control measures. However the WHO and the 
IUATLD, in the light of discussions in several 
international fora, have replaced the term primary 
resistance by the term “drug resistance among new 
cases” and acquired resistance by the term “drug 
resistance among previously treated cases(4). 
B. Causes of drug resistance 
Several explanations are given for the 
emergence of drug resistance. These include: 
* Deficient or deteriorating TB control 
programmes resulting in inadequate 
administration of effective treatment 
Poor case holding, administration of sub- 
standard drugs, inadequste or irregullar drug 
supply and lack of supervision 
Ignorance of health care workers in 
epidemiology, treatment and control of TB 
* 
* Improper prescription of regimens 
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Interruption of chemotherapy due to side effects 
Non-adherence of patients to the prescribed drug 
therapy 
Availability of anti-TB drugs across the counter, 
without prescription 
Massive bacillary load 
Illiteracy and low socio-economic status of the 
patients 
The epidemic of HIV infection 
Laboratory delays in identification and 
susceptibility testing of M. tuberculosis isolates 
Lack of the use of uniform laboratory methods, 
use of reliable drug powders and quality control 
methods 
Use of anti-TB drugs for indications other than 
tuberculosis. 
The major contributing factors towards development 
of drug resistance are summarized in Fig.1. 
C. Mechanism of drug resistance 
Drug resistance in M. tuberculosis occurs by 
random, single step, spontaneous mutation at a low 
but predictable frequency, in large bacterial 
populations. There is also no convincing role for the 
role of plasmids or transposons as in other pathogens. 
The probability of incidence of drug resistant mutants 
is 10-8 for rifampicin, while for isoniazid and some of 
the other commonly used drugs it is 10-6. Therefore, 
the probability for resistance to both isoniazid and 
rifampicin to develop is 10-14, which is much larger 
than the number of organisms present in a medium 
sized cavity in a patient with open pulmonary TB. As 
such, the probability for MDR-TB to develop is an 
iatrogenic problem. 
D. Transmission of drug-resistant TB 
For several years, drug resistant strains of M. 
tuberculosis were considered to be less infectious than 
the drug susceptible ones. Hence drug resistance in a 
TB patient was considered as a problem for the 
concerned patient only and not for the community. 
However, recent studies have demonstrated that the 
drug resistant mutants are equally infectious and can 
cause severe disease in an individual exposed to the 
same(4). 
E. Detection of drug resistance 
The conventional methods of culture, 
identification and drug susceptibility testing of the 
isolated organism requires a minimum of 10-12 weeks. 
Although most widely used, the long waiting period in 
obtaining the results by this method may delay the 
initiation of proper treatment, resulting in the patient 
transmitting drug-resistant infection in the 
community. 
The use of direct sensitivity tests, especially to 
isoniazid and rifampicin, by inoculating the drug- 
containing slopes along with drug-free culture slopes 
has resulted in a saving of at least 4 weeks in obtaining 
the resistance status(5,6). Although found to be useful, 
the disadvantage of this method is that it is not very 
useful in smear-negative and paucibacillary 
specimens. Available evidence from TRC on a limited 
number of strains using a single LJ slope containing 
critical concentrations of both isoniazid and rifampicin 
have shown promising results (unpublished findings). 
A simple, inexpensive slide culture drug 
susceptibility test(7) that can provide results in a week 
has also shown great promise. This method, however, 
has been discontinued at present for fear of handling 
and hepatitis infected blood. 
The automated radiometric BACTEC method 
provides results in less than 3 weeks and has shown a 
good correlation with conventional methods(8). 
However, the method is expensive and requires 
considerable technical competence. In recent years, 
other non-radiometric faster methods such as the 
mycobacterial growth indicator test (MGIT) have been 
developed (Becton Dickinson). 
A highly sensitive and specific method using a manual 
bacteriophage-based test to correctly identify 
rifampicin susceptibility in clinical strains of 
Mycobacterium tuberculosis after growth in a semi- 
automated liquid culture system, FASTPlaqueTB-RIF, 
has been reported reecently(9). 
Polymerase chain reaction (PCR), single 
stranded conformation polymorphism (SSCP) and line 
probe assay (LIPA) have made possible the rapid 
identification of rifampicin-resistant M. 
Tuberculosis(l0). The results become available within 
24 hours. However, an analogous setting for isoniazid 
resistance is reported to be less favorable, since more 
than one gene is probably involved in isoniazid 
resistance. 
Restriction fragment length polymorphism 
(RFLP) using insertion element IS 986/IS 6110 based 
DNA probe has also been reported to be successful in 
epidemiological studies in MDR-TB outbreaks. It has 
also been shown that clustering is more common among 
patients with MDR isolates than unique isolates(l1). 
The newer methods have resulted in cutting 
down the time interval between collection of the 
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specimen and the receipt of results to 2-3 weeks. 
However, these methods require considerable technical 
expertise and impose financial constraints in a routine 
laboratory set up in the developing nations. 
F. The WHO/IUATLD Global Project on Drug 
Resistance 
Due to difficulties in collecting comparable data 
from different corntries/regions and in order to assist 
NTPs in establishing policies for drug resistance 
surveillance and programme monitoring, the global 
tuberculosis programme (GTB) of WHO and IUATLD 
proposed, in 1994, a global tuberculosis surveillance 
programme. The objectives of this programme included: 
a) to collect data on the global extent and severity of 
anti-TB drug resistance in a standardized manner at 
country/regional level, b) to monitor drug resistance 
levels in countries identified as a priority for assistance 
and c) proper bacteriological methodology in national 
laboratories through an  international system of 
proficiency testing. Guidelines for the performance of 
anti-TB drug resistance surveillance were developed 
including standard definitions and procedures for 
implementation(12). 
G. The global drug resistance scenario 
During the period 1994-99, a total of 72 
surveillance projects on anti-TB drug resistance in 65 
countries have been completed. This included 31% of 
all the countries in the world covering approximately 
33% of the world's population and 28% of the reported 
TB cases(l3). However, the Global Project had the 
highest coverage in the Americas (89%) and the 
Western Pacific Region (47%), while the lowest 
coverage was observed in South-East Asia (17%) and 
the Eastern Mediterranean Region (12%). The median 
value for any drug resistance among new cases was 
found to be 11% (range 1-7%-41%). The lowest median 
value was 0.6% for any ethambutol resistance and the 
highest was 7% for any isoniazid resistance. Resistance 
to all the four drugs tested was found to range from 
0% in 24 geographical settings to 8.5% in Estonia. The 
median prevalence of MDR-TB in new cases of 
tuberculosis was 1% (range 0%-14.1%). The highest 
prevalence was reported from Estonia ( 14.1%) followed 
by China, Latvia, Ivanovo Oblast, Tomsk Oblast 
(Russian Federation) and Iran (5%). 
Among previously t reated cases median 
prevalence of resistance to any drug was 33.4% (range 
0%-93.8%). The lowest median value was 5.5% for any 
ethambutol resistance and the highest was 21.9% for 
any isoniazid resistance. The median prevalence of 
MDR-TB among treated cases was 9.3%, ranging from 
0% in four geographical settings to a maximum of 
48.2% in Iran. Further, 28 geographical regions 
provided annual data for 2-4 years for the assessment 
of trends in drug resistance over the period in new 
cases of TB. Accordingly, only France and the United 
States reported a significantly downward trend in 
MDR-TB while a statistically significant increase was 
noticed in Estonia(l3). 
The main findings of the Global Tuberculosis 
Programme are summarized in Table 1. 
H. Drug Resistance studies in India 
Although drug resistance in tuberculosis has 
been reported frequently during the last four decades, 
the available information is localized, inaccurafe or 
incomplete(l4) .Further, drug resistance is diagnosed 
presumptively based on the lack of improvement in 
the patient following chemotherapy or a relapse of 
symptoms. In order to formulate a national treatment 
policy, reliable and periodic updates on the prevalence 
of drug resistance for the entire country is needed, 
which would serve as an indication of the transmission 
of drug resistant organisms as well as the efficacy of 
the NTP. In view of the large size of the country and 
several other administrative as well as financial 
constraints, surveys of drug resistance at a national 
level are logistically difficult to undertake. Most of the 
published reports on drug resistance in India, with the 
exception of studies reported from the Tuberculosis 
Research Centre (TRC) in  Chennai(l4-21), the  
National Tuberculosis Institute in Bangalore(22,23) 
and a few others(l4), are deficient in several aspects, 
such as lack of standardized methodology, improper 
elicitation of previous treatment history, sample 
selection, non-uniformity in bacteriological procedures, 
sub-standard drug powders used for susceptibility 
testing and lack of quality assurance studies(14). Some 
of the more important reports are reviewed below: 
I. Initial drug resistance in India 
The Indian Council of Medical Research (ICMR) 
undertook drug resistance studies during 1965-67 in 
nine urban areas of the country(l7,18). It should be 
emphasized here that this exercise was not a 
surveillance study and did not use strict sampling 
techniques, the centres being selected more for logistic 
considerations than  for epidemiological reasons. 
Sputum specimens collected from all patients 
a t tending chest clinics were tested for drug 
susceptibility to streptomycin, isoniazid, PAS and 
thioacetazone. The first study was on patients who had 
denied any history of previous treatment while in the 
second study patients with and without previous 
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chemotherapy were included. The results showed that 
in the first study resistance to isoniazid ranged from 
11-20%, to streptomycin from 8-20% and to both drugs 
from 4-11%.The second study showed resistance to 
isoniazid to range from 15-69%, to streptomycin grom 
12-63% and to both drugs from 5-58%. Further the level 
of drug resistance was proportional to the duration of 
previous treatment. 
A decade later, a study was conducted to assess 
the prevalence of primary drug resistance at the 
Government Chest Institute and Chest Clinic of 
Government Stanley Hospital (GCI-SH), Madras(24). 
The results of the study were similar to those in earlier 
ICMR surveys, indicating that the prevalence of initial 
drug resistance had not risen during the span of ten 
years. However, the above studies were undertaken 
in the pre-rifampicin era and are not of relevance in 
the present setting. 
During the 1980s, though the levels of initial 
drug resistance to isoniazid and streptomycin in 11 
reports (Table 2) were similar to those in the earlier 
studies, rifampicin resistance was observed in all the 
centers studied except Gujarat(19,21-23,25-27). The 
level of MDR-TB in all the centers (except Wardha) 
was observed to be less than 5%. The reason for the 
emergence of rifampicin resistance during this period 
may be the introduction of short course chemotherapy 
(SCC) regimens containing rifampicin. Further, a 
higher level of initial drug resistance to isoniazid 
(32.9%) was observed among the rural population in 
Kolar compared to the urban patients, contradicting a 
Korean study(28), where a much higher level of initial 
resistance was seen among urban patients, attributed 
to easy access to the antituberculosis drugs. There was 
also an  increase in the proportion of initial drug 
resistance to rifampicin (4.4%) encountered in this 
rural population in Karnataka. 
In the early 1990s, a retrospective study done 
at New Delhi showed a high level of initial drug 
resistance to isoniazid (18.5%) and a low level of 
resistance to rifampicin(29). 
Data on the prevalence of drug resistance from 
the Army Hospital, Pune showed a very low level of 
initial resistance to isoniazid and the authors have 
explained that this lower level of drug resistance in 
this population could be due to the minimal chance of 
indiscriminate exposure of anti-TB agents prior to 
reporting to the hospital(30). 
Studies  undertaken by the  Tuberculosis 
Research Centre, Chennai, during 1997-99 in Tamil 
Nadu State(l5) as well as the districts of North Arcot 
and  Raichur( 16) revealed initial resistance to 
rifampicin to range from 2.5-4.4% while the prevalence 
of MDR-TB was around 3%. Interim results of a study 
jus t  completed in  the Wardha district revealed 
resistance to isoniazid, rifampicin and to both drugs 
to be 15.2%, 0.5% and 0.5% respectively (TRC, 
unpublished data). 
However, it should be emphasized that several 
of these reports, except those from the TRC, NTI and 
the  Armed Forces Group, may have inherent  
limitations due to flaws in methodology and hence need 
to be interpreted with caution. 
J. TRC studies on prevalence of primary drug 
resistance 
Drug resistance data from controlled clinical 
trials on short course chemotherapy with rifampicin- 
containing regimens conducted at the Tuberculosis 
Research Centre (TRC), Chennai involving almost 
3500 patients over the last 3 decades is shown in 
Figure 2. For isoniazid, the resistant rate ranged from 
10-16% and for streptomycin from 8-13%. Resistance 
to rifampicin started appearing in 1990s and still 
remains a t  around 1%. Resistance to both isoniazid 
and rifampicin (MDR) is 1% or less. These figures 
could be considered to represent an accurate picture 
of true primary resistance in view of the detailed and 
repeated questioning methods used for eliciting history 
of previous treatment from the patients. 
K. Acquired drug resistance in India 
The rates of acquired resistance are invariably 
higher than those of initial resistance, though data on 
acquired resistance is limited. The findings of studies 
on acquired resistance are shown in Table 3. The 
longitudinal trend of drug resistance noted by Trivedi 
and Desai(26) during the 1980s in Gujarat showed that 
in treatment failure or relapsed patients, resistance 
to rifampicin increased from 2.8% in 1980 to 37.3% in 
1986 and to isoniazid from 34.5% to 55.8%. From this 
study it was presumed that high level of rifampicin 
resistance was almost entirely acquired. During this 
period MDR-TB was of the order of 30%. 
In the course of a study conducted by the TRC 
in North Arcot district to compare the efficacy of SCC 
with conventional (non-SCC) chemotherapy, it was 
found that frequency of acquired drug resistance was 
67% to isoniazid, 26% to streptomycin and 12% to 
rifampicin; in addition, 11% of the strains tested were 
resistant to both isoniazid and rifampicin(21). A New 
Delhi study(29) in the 90s also showed a higher leverl 
of acquired resistance to isoniazid and rifampicin which 
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is almost similar to that of the Gujarat report(26). A 
study conducted by the Institute of Thoracic Medicine, 
Chennai aimed at finding out the prevalence of 
tuberculosis resistance in four District tuberculosis 
Centres of Tamil Nadu, showed that  acquired 
resistance was 63%, out ofwhich 23.5% was resistance 
to single drug and 39.5% to more than one drug. 
Resistance to isoniazid and rifampicin (MDR-TB) was 
reported in 20.3%(31). 
Studies undertaken by the  Tuberculosis 
Research Centre, Chennai during 1997-2000 in the 
entire state of Tamil Nadu(l5), North Arcot and 
Raichur districts(l6) as well as in Wardha 
(unpublished) revealed the incidence of MDR-TB to 
vary from 25-100%. However, these data are based 
on very small numbers of patients. Since these studies 
were not designed to obtain a true picture of acquired 
resistance in these areas, the results presented should 
be interpreted with caution. 
An ongoing study, with INCLEN funding, in 
eight different settings in India (two in Maharashtra, 
three in Tamil Nadu and one each in Uttar Pradesh, 
Kerala and Delhi) is expected to yield considerable data 
on the magnitude of drug-resistant tuberculosis in the 
country. 
L. Management of Multi-drug resistant 
tuberculosis 
The emergence of drug resistant strains is 
known to reduce the efficacy of treatment. Strains 
resistant to isoniazid and streptomycin (H/S/SH) 
neither pose a major problem nor affect the result of 
treatment in a big way provided proper regimens are 
used. It has been well documented that the currently 
available short-course regimens of six months duration 
cures 94-97% of patients with resistance to 
streptomycin, isoniazid or  to both drugs(32). Studies 
at the TRC have shown that in patients with resistance 
to streptomycin, isoniazid or both drugs, only 2%, 8% 
and 17% respectively failed to respond when treated 
with appropriate regimens(33). On the contrary, the 
outcome of treatment of patients infected with 
organisms resistant to rifampicin and isoniazid (MDR) 
have a high rate of treatment failure. Studies at the 
TRC had reported that 35 of 38 patients with MDR 
failed to respond with conventional regimens(33). 
Patients infected with MDR strains require longer 
duration of therapy and may die of tuberculosis or 
continue to have active tuberculosis despite optimal 
therapy. In a retrospective analysis of 171 patients 
treated over a ten-year period (1973-83) at the National 
Jewish Hospital, Denver, the overall favourable 
outcome was only a little over 50%(34). In the Cape 
Town Province of South Africa, the 5-year outcome of 
240 MDR-TB patients was only 33% cure(35). 
Experience at the Tuberculosis Research Centre with 
MDR-TB has been equally discouraging. In about 170 
patients with MDR-TB over a 12-year period (1986- 
97), only one third had a favourable outcome and 
another one-third had died(36). 
However, not all reports are so grim. In a 
retrospective analysis reported from South Korea on 
107 patients with MDR-TB treated with at least four 
drugs to which they had not been exposed to before, or 
to which they were known to be susceptible, 52(82.5%) 
of 63 patients followed up responded to treatment and 
there were no subsequent relapses or TB-related 
deaths, when followed up for 17 months(37). Recent 
studies at the TRC have shown promising results with 
the use of added ofloxacin in the regimens in treating 
MDR-TB. While interim reports appear promising, a 
long term follow up is needed to draw valid conclusions 
(TRC, unpublished observations). The fluoroquinolones 
have been shown to have marked anti-mycobacterial 
activity and are being increasingly used in the 
treatment of MDR-TB. However, this class of drugs is 
also widely used for a variety of respiratory and other 
infections. Caution has  to be exercised as 
indiscriminate use will lead to the development of 
resistance to this class of drugs also. 
The value of some of the older drugs in the 
treatment of MDR-TB has to be emphasized. Many of 
the younger patients of today have never received PAS 
or thioacetazone in the past and these drugs can be 
used with success. In the recent past, there have been 
a few reports of the value of B-lactam antibiotics used 
along with lactamase inhibitors(38), rifabutin(39) and 
recombinant human interleukin 2(40) in the 
management of MDR-TB. However, these studies are 
all based on small numbers of patients and need to be 
evaluated further in well designed controlled clinical 
trials. 
III. CONCLUSIONS 
In view of the results so far observed, there is 
no clear evidence of an increase in the prevalence of 
initial drug resistance in India over the years. 
However, relatively high prevalence of acquired 
resistance has been reported from Gujarat, New Delhi, 
Raichur and North Arcot districts. When compared to 
the global prevalence of drug resistance, initial drug 
resistance is found to be marginally less while that of 
acquired resistance is much higher in India in 
specialized settings. The magnitude of drug resistance 
problem to a large extent is due to acquired resistance. 
The prevalence of MDR-TB also is found to be at a low 
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level in most of the regions of India. Since paediatric 
cases and resistance in them are mirror reflection of 
adult tuberculosis cases, the low level of resistance to 
isoniazid and streptomycin with 5-10% and 2-11.4% 
respectively and with a nil resistance to rifampicin 
reported so far in Indian children really indicates that 
there is apparently no alarming increase in the 
incidence of initial MDR tuberculosis cases. However, 
these studies require to be repeated in different regions 
and in diverse settings to reconfirm this belief. 
A strong tuberculosis programme that can 
reduce the incidence of drug resistance in the 
community and particularly directly observed therapy 
(DOTS) which is cost effective, will prove to be effective 
in treatment completion and in turn proved to be 
effective against emergence of drug resistance. Newer 
drugs for tuberculosis are unlikely to come up in the 
near future and hence the key to success remains in 
adequate case finding, prompt and correct diagnosis 
and effective treatment of infective patients for 
prevention of drug resistance. 
All physicians and health care personnel 
involved in managing tuberculosis patients should 
strictly adhere to the treatment policies of the 
government in implementing DOTS and also to ensure 
completion of treatment which would eventually result 
in the reduction in the prevalence of MDR-TB in the 
community as it has been seen elsewhere. 
Apart from a strong tuberculosis control 
programme, there is also need for a continuous or 
periodic survey of drug resistance, with an emphasis 
on internal quality control and external quality 
assessment, which will provide information on the type 
of chemotherapy to be used for the treatment of 
patients and also serve as a useful parameter in the 
evaluation of current and past chemotherapy 
programmes. 
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Drug 
Isoniazid 
Streptomycin 
Rifampicin 
Ethambutol 
MDR 
(range) 
Table 1. Global antituberculosis drug resistance situation 
Range (%) of drug resistance during the period 
1994-1997 1996-1999 
Initial Acquired Initial Acquired 
1.5-31.7 5.3-69.7 0.0-28.1 0.0-81.3 
0.3-28.0 0.0-82.6 0.3-32.4 0.0-52.4 
0.0-16.8 0.0-57.9 0.0-15.8 0.0-50.0 
0.0-9.9 0.0-29.6 0.0-11.1 0.0-32.1 
0.0-14.4 0.0-58.0 0.0-14.1 0.0-48.2 
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SL 
No. 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
Location 
9 Centres-ICMR I 
9 Centres-ICMR II 
GCI -SH, Chennai 
Bangalore 
Wardha 
Gujarat 
Bangalore 
North Arcot 
Pondicherry 
Kolar 
Raichur 
North Arcot * 
North Arcot * 
Jaipur 
New Delhi 
Military Hosp.Pune 
Tamil Nadu State 
North Arcot 
Raichur 
Wardha** 
* 
** 
Period 
1964-65 
1965-67 
1976 
1980's 
1982-89 
1983-86 
19 8 5 - 8 6 
1985-89 
1985-91 
1987-89 
1988-89 
1989-90 
1989-98 
1989-91 
1990-91 
1992-93 
1997 
1999 
1999 
2000 
No. of 
isolates 
1838 
851 
254 
436 
323 
570 
588 
2779 
1841 
292 
244 
241 
747 
1009 
324 
473 
384 
282 
278 
197 
Any resistance (%) to 
S H R SH HR 
14.7 12.5 ND 6.5 ND 
13.8 15.5 NA ND 
14.2 15.4 ND 4.7 ND 
5.7 17.4 3.0 3.9 1.1 
14.9 21.4 8.0 8.0 5.3 
7.4 13.8 0.0 4.2 0.0 
4.8 17.3 2.9 3.0 1.4 
11.6 21.3 1.7 8.0 1.6 
8.1 10.8 1.0 3.7 0.8 
5.1 32.9 4.4 4.1 3.4 
11.4 19.3 3.3 6.6 3.3 
12.9 2.5 1.7 
19.0 11.8 4.4 
7.6 10.1 3.0 1.7 0.9 
ND 18.5 0.6 ND 0.6 
8.2 3.2 4.0 2.1 1.0 
6.8 15.4 4.4 4.4 3.4 
12.4 23.4 2.8 8.5 2.8 
7.2 18.7 2.5 4.0 2.5 
7.6 15.0 0.5 3.0 0.5 
Tuberculosis Research Centre, unpublished fin ings 
Tuberculosis Research Centre, interim findings, unpublished 
Table 3 Summary of studies on acquired drug resistance among M. tuberculosis olates in India 
S.No. Location Period No. of Any resistance (%) to 
isolates H R HR 
1 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
Gujarat 
Gujarat 
Wardha 
North Arcot 
Raichur 
N.Delhi 
Tamil Nadu (4 dts) 
Tamil Nadu State 
North Arcot 
Raichur 
Wardha** 
1980-86 
1983-86 
1982-89 
1988-89 
1988-89 
1990-91 
1996 
1997 
1999 
1999 
2000 
1574 
1259 
302 
560 
111 
81 
162 
16 
16 
11 
9 
47.7 
81.1 
47.0 
67.0 
52.3 
60.5 
(50.0)* 
(81.0) 
(100.0) 
(78.0) 
- 
28.3 
33.0 
12.6 
12.0 . 
17.1 
33.3 
(25.0) 
(69.0) 
(100.0) 
(78.0) 
- 
30.2 
9.6 
10.9 
17.1 
33.3 
20.3 
(25.0) 
(69.0) 
(100.0) 
(78.0) 
* Brackets indicate that the percentage is based on a total of less than 25 
** TRC, unpublished interim findings 
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